Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2011-03-01
2011-03-01
Zeman, Mary K (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C702S020000, C703S011000, C703S012000, C703S013000, C707S700000
Reexamination Certificate
active
07899625
ABSTRACT:
A robust classification method for cancer detection from mass spectrometry data includes inputting the mass spectrometry data, preprocessing the spectrometry data, conducting robust feature selection, generating predictions for the test data sets using multiple data classifiers, the multiple data classifiers including artificial neural networks, support vector machines, weighted voting on data patterns, classification and regression trees, k-nearest neighbor classification, and logistic regression, and constructing and validating a meta-classifier by combining individual predictions of the multiple data classifiers to generate a robust prediction of a phenotype. The test data sets are used exclusively for validation of the meta-classifier.
REFERENCES:
patent: 6898533 (2005-05-01), Miller et al.
patent: 7542959 (2009-06-01), Barnhill et al.
patent: 2002/0145425 (2002-10-01), Ebbels et al.
patent: 2003/0229451 (2003-12-01), Hamilton et al.
patent: 2005/0209785 (2005-09-01), Wells et al.
Ornstein, DK, et al., “Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.”, J. Urol. Oct. 2004;(4 Pt 1): 1302-5.
Posadas, EM, et al., “Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.”, Curr Opin Oncol. Sep. 2004;16(5): 478-84.
Shau, H, et al., “Proteomic profiling of cancer biomarkers”, Briefings in Functional Genomics and Proteomics, vol. 2, No. 2, pp. 147-158, Jul. 2003.
Semmes, O. John, “Defining the Role of Mass Spectrometry in Cancer Diagnostics”, Cancer Epidemiol Biomarkers Prev. vol. 13, No. 10, Oct. 2004.
Lev Bar-Or, Ruth, et al., “Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study”, PNAS, vol. 97, No. 21, pp. 11250-11255, Oct. 10, 2000.
Weng, Zheng, et al., “Mass Spectrometric Analysis of Protein Markers for Ovarian Cancer”, Clincal Chemistry, vol. 50, pp. 1939-1942, 2004.
Liotta, Lance A., et al., “High-resolution serum proteomic patterns for ovarian cancer detection”, Endocrinology Journals, vol. 11, pp. 585-587, 2004.
Grizzle, William E., et al., “Serum protein expression profiling for cancer detection: Validation of a SELDI-based approach for prostate cancer”, Disease Markers, vol. 19, pp. 185-195, (2003,2004)IOS Press.
Wagner, Michael, et al., “Computational protein biomarker prediction: a case study for prostate cancer”, BMC Biomformatics, vol. 5, No. 26, pp. 1471-2105, 2004.
Schwartz, Sarah A., et al., “Protein Profiling in Brain Tumors Using Mass Spectrometry: Feasibility of a New Technique for the Analysis of Protein Expression”, Clinical Cancer Research, vol. 10, pp. 981-987, Feb. 1, 2004.
Diamandis, Eleftherios P., “Point Proteomic Patterns in Biological Fluids: Do they represent the future of Cancer Diagnositcs?”, Clinical Chemistry, vol. 49, No. 8, pp. 1272-1278 (2003).
Diamandis, Eleftherios P., “Mass Spectrometry as a Diagnostics and a Cancer Biomarker Discovery Tool: Opportunties and Potential Limitations”, Molecular & Cellular Proteomics, MCP Papers in Press, Feb. 28, 2004.
Alfonso, P., et al., “Proteomic analysis of lung biopies: Differential protein expression profile between peritumoral and tumoral tissue.”,Proteomics, vol. 4, No. 2, pp. 442-447, Feb. 2004.
Eschrich, S., et al., “DNA microarrays and data analysis: an overview.”, Surgery, vol. 136, No. 3, pp. 500-503, Sep. 2004.
Huang, E., et al., “An overview of genomic data analysis*1.”, Surgery, vol. 136, No. 3, pp. 497-499, 2003.
White, CN, et al., “Bioinformatics strategies for proteomic profiling.”, Clinical Biochem., vol. 37, No. 7, pp. 636-641, Jul. 2004.
Petricoin, EF, et al., “Clincal proteomics: Applications for prostate cancer biomarker discovery and detection.”, Urol. Oncol., vol. 22, No. 4, pp. 322-328, Jul.-Aug. 2004.
Laronga, C, et al., “SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.”, Dis. Markers, vol. 19, Nos. 4 and 5, pp. 229-238, 2003-2004.
Yates, JR 3rd., “Mass spectral analysis in proteomics.”, Annu. Rev. Biophys. Biomol. Struct., vol. 33, pp. 297-316, 2004.
Alexe Gabriele
Bhanot Gyan Vatsaraja
Levine Arnold J.
Venkataraghavan Babu
Alexanian Vazken
International Business Machines - Corporation
McGinn IP Law Group PLLC
Zeman Mary K
LandOfFree
Method and system for robust classification strategy for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and system for robust classification strategy for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and system for robust classification strategy for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2718315